Marshall Wace LLP raised its position in shares of Kadmon Holdings Inc (NYSE:KDMN) by 63.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,704,894 shares of the company’s stock after purchasing an additional 662,773 shares during the period. Marshall Wace LLP owned about 2.16% of Kadmon worth $6,803,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Highland Capital Management LP bought a new stake in Kadmon during the 2nd quarter valued at $399,000. Voya Investment Management LLC bought a new stake in Kadmon during the 2nd quarter valued at $101,000. Renaissance Technologies LLC bought a new stake in Kadmon during the 2nd quarter valued at $1,026,000. VHCP Management II LLC bought a new stake in Kadmon during the 2nd quarter valued at $5,632,000. Finally, DAFNA Capital Management LLC bought a new position in shares of Kadmon in the 2nd quarter worth $261,000. 69.66% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently commented on the company. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Wednesday, July 11th. HC Wainwright set a $25.00 price target on Kadmon and gave the stock a “buy” rating in a research report on Monday, August 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Kadmon has a consensus rating of “Buy” and an average price target of $11.45.
Kadmon (NYSE:KDMN) last released its quarterly earnings results on Thursday, August 9th. The company reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.50. The company had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.90 million. sell-side analysts predict that Kadmon Holdings Inc will post -0.94 EPS for the current fiscal year.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Article: Find a Trading Strategy That Works
Want to see what other hedge funds are holding KDMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kadmon Holdings Inc (NYSE:KDMN).
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.